Veranex provider of the first purpose-built, global service platform for the medtech industry, today announced that it has acquired T3 Labs, a highly reputable preclinical laboratory located in Atlanta, Georgia. This acquisition solidifies Veranex’s commitment to expanding its preclinical footprint in North America, deepening its therapeutic expertise, and providing customers with enhanced flexibility.
Veranex became the industry’s first true concept through commercialization service provider focused on the medical device and IVD industry. Acquiring leading medtech brands with 1,300+professionals, in 19 locations across 13 countries, by the end of 2021 Veranex had formed a platform unique in the world of medical technology.
The Commercialization Platform:
- Product Design & Engineering
- Regulatory & Quality Consulting
- Preclinical Services
- Clinical Research and Data Management
- Market Access and Health Economics
The group of companies brought together by Veranex offers over 35 years of experience successfully bringing products to market, hundreds of satisfied customers, over 2,500 projects completed, and more than 700 patents secured on behalf of our customers.
Veranex is unique in that it also offers FDA registered small batch manufacturing of medical devices and IVD instrumentation and consumables.
Veranex offers unparalleled medical device and IVD expertise: design and engineering, human factors, regulatory affairs, quality systems, preclinical studies, clinical trial strategy/execution, clinical data management, reimbursement, commercial strategy, market access… this is a unique one-stop-shop offer in the world for innovative companies seeking expert help to take their new medical technologies into the market.
In diagnostics we work on the development of point of care instruments, cartridge design and development, pre-built technology and proof of concept prototyping, centralized lab equipment development, across all the fields of IVD: molecular diagnostics (one of our fortes), coagulation monitoring, sequencing, Antibiotic Susceptibility Testing, hematology analyzers, Liquid Biopsy, etc.
At SLAS our representatives Fernando Oliveira, Raffaele Mazzei and Juan Roman are looking forward to meet with innovative start-ups and leading IVD companies looking into bringing novel IVD instrumentation into the market.
Innovative malaria prodrug targets liver, enhances efficacy while reducing toxicity, preclinical studies show